Pfizer's LORBRENA Shows Unprecedented 7-Year Survival in Lung Cancer Trial
Event summary
- Pfizer's LORBRENA demonstrated a 55% progression-free survival rate at seven years in the CROWN trial, compared to 3% for XALKORI.
- The trial showed an 81% reduction in disease progression or death risk with LORBRENA versus XALKORI.
- LORBRENA prevented and controlled brain metastases, with a 94% reduction in intracranial progression risk.
- 44% of patients in the CROWN trial were still receiving LORBRENA at seven years, compared to 3% on XALKORI.
The big picture
Pfizer's LORBRENA trial results represent a significant milestone in the treatment of advanced non-small cell lung cancer, showcasing the potential for long-term disease control. The data underscores the strategic importance of third-generation ALK inhibitors in the oncology market, particularly in addressing brain metastases. This could reshape treatment paradigms and competitive dynamics in the ALK-positive NSCLC space.
What we're watching
- Market Differentiation
- Whether LORBRENA's long-term efficacy data will solidify its position as a leading treatment for ALK-positive NSCLC.
- Regulatory Approvals
- The pace at which Pfizer can secure additional approvals for LORBRENA in new markets based on these results.
- Competitive Response
- How competitors like XALKORI will respond to LORBRENA's demonstrated superiority in long-term outcomes.
Related topics